In a recent real-life study of patients with psoriatic arthritis (PsA), Tofacitinib exhibited a reasonably good retention rate in these patients who have not responded well to other treatments. Ignacio Braña et al. aimed to investigate the persistence and safety of Tofacitinib in real-world conditions.

The study involved 72 PsA patients who received a minimum of single dose of Tofacitinib. Notably, more than 70% of these patients had already undergone three or more lines of therapy before starting Tofacitinib. Results from the study revealed that Tofacitinib exhibited a good retention rate, with a median survival of 13 months. Furthermore, the one-year retention rate was found to be 52.7%. Importantly, the survival of Tofacitinib was not significantly influenced by factors such as sex, duration of the disease or comorbidities. Younger patients and those experiencing enthesitis, were less likely to stop taking this therapy, suggesting Tofacitinib to be mainly beneficial for patients with refractory PsA and enthesitis.

In terms of safety, the study reported an overall adverse event rate of 52.9 per 100 person-years, with the majority of adverse events occurring within the first 6 months of the treatment, concluded Braña.